Pfizer Investigational Site
New Haven, Connecticut, 06511, United States
NCT Number: NCT00722306
To determine the mass balance of PD 0200390
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
New Haven, Connecticut, 06511, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
Time frame: 2 days
Time frame: 2 days
Looking for future studies?
Notify MePfizer
Industry
A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07840924
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Arnhem, Netherlands
View Trial DetailsNCT07559305
Adults, Dyssomnias
Hong Kong
View Trial DetailsNCT06463197
Dyssomnias, Insomnia
Hong Kong
View Trial DetailsNCT04831385
Diabetes Mellitus, Diabetes Mellitus, Type 2
Hong Kong
View Trial Details